Neurogene (NGNE) Return on Equity (2014 - 2026)

Neurogene has reported Return on Equity for 13 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.03% in Q4 2022, with the low at 0.37% in Q4 2023.
• Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.0% in 2024.
• Annual changes were most pronounced in 2023 — Return on Equity plunged 40 bps — and 2024, when it soared 37 bps.
• Neurogene's Return on Equity stood at 0.03% in 2022, then sank by 1427 bps to 0.37% in 2023, then surged by 99 bps to 0.0% in 2024, then slipped by 4 bps to 0.0% in 2025, then slipped by 15 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.